Your Mounjaro Maintenance Plan: The Decisions That Shape It

How do you and your prescriber decide which dose to hold at?

The answer is almost always: the dose where weight loss is meaningful and side effects are genuinely manageable, not the highest dose on the label. Tirzepatide is a dual GIP and GLP-1 receptor agonist licensed in the UK for weight management, and its six strengths (2.5mg through to 15mg) are designed to give prescribers flexibility, not a ladder you are obliged to climb to the top of. Some people find 5mg feels right; others move steadily to 10mg or 12.5mg before side effects or clinical response signal a stopping point.

The 2.5mg starting dose exists purely to help your system adjust. It is not expected to produce substantial weight loss, and holding there long-term would not constitute a maintenance plan in any clinical sense. From there, your prescriber reviews your response (weight trend, tolerability, any relevant health changes) before each step. The concept of a maintenance dose is simply the point where titration stops because the balance is right.

There is also something sometimes called the golden dose: the informal term for the strength at which weight loss is strong and side effects are minimal. It is not a clinical category, but it captures a real phenomenon. Some patients land there at 7.5mg; others at 15mg. Discovering yours takes time and honest clinical dialogue. NICE's appraisal of tirzepatide (TA1026) recommends reviewing continuation if less than 5% weight loss has occurred after six months at the highest tolerated dose, which is a useful benchmark when you and your prescriber are evaluating whether to push further or stay put.

What does 'maintenance' actually mean day to day?

Once titration is complete, the practical rhythm of a Mounjaro maintenance plan is simpler than the titration phase. One injection per week, same day, rotating sites between abdomen, thigh and upper arm. The pen lives in the fridge (most people tuck it in the door) until around 30 minutes before the injection, when it can come to room temperature. Always check the Patient Information Leaflet for the exact storage and out-of-fridge window; we do not reproduce those figures here because the SmPC is the authoritative source.

Gastrointestinal side effects (nausea, looser stools, reflux) tend to be most noticeable during dose increases. Many people find they settle considerably once a dose is held steady for a few weeks. If they do not settle, that is information: it may mean the maintenance dose needs revisiting downward rather than pushing up.

Clinically, maintenance is not a hands-off phase. At nume, a prescriber reviews every repeat before it is dispatched, not as a box-tick but because weight, health status and medicines can all change. The clinical team may ask for updated weight, flag interactions, or note that your circumstances have changed since the last supply. That review is how the plan stays a plan rather than a prescription running on autopilot.

Can the maintenance dose change, and what triggers a review?

Yes. Maintenance is a best current position, not a permanent fixture. Several things can prompt a prescriber to revisit it: weight plateauing when a higher dose is still tolerated, persistent side effects that suggest the current dose is too high, a significant change in health status, or the introduction of a new medicine that affects the picture.

There is also the question of whether 7.5mg (or 5mg) is genuinely a long-term maintenance level for you, or a comfortable holding point before moving further. Those are different things, and a good prescriber will flag the distinction. What is not appropriate is changing your own dose between supplies, or holding at a titration dose indefinitely without clinical input.

If you are thinking about what happens after a period of treatment (what maintenance looks like once you stop tirzepatide) that is a separate conversation worth having with your prescriber before rather than after you stop, because weight management strategies work better when they are planned.

Cost, access and what a maintenance plan looks like through a private pharmacy

On the NHS, tirzepatide is currently available through a phased rollout with strict eligibility criteria; many people in the UK are accessing it privately while waiting lists remain long. Through a regulated private route, the maintenance phase looks operationally similar (same medicine, same clinical review requirement) but the commercial picture is worth understanding. Prices vary by dose and by provider, and the higher maintenance doses cost more per pen than the starter strengths. The Eli Lilly UK price increase from September 2025 changed the market significantly, with higher-dose pens now carrying notably higher list prices than before.

At nume, the price you see includes the clinical consultation, the prescription, the medicine and free next-working-day delivery, no separate consultation fee, no subscription. Current treatment pricing is shown on the treatment page. We are not the cheapest option available, and that is a deliberate choice: a maintenance plan for a prescription medicine is a clinical relationship, not a commodity purchase. The NHS medicines page for tirzepatide covers the clinical background clearly if you want a second reference point alongside your prescriber's guidance. Worth reading.